– FRANCE, Montpellier – Sensorion (EPA: ALSEN), a pioneering clinical-stage biotechnology company which specializes in gene therapies in the ear, today announced the appointment of Khalil Barrage as Interim Chair of the Board of Directors, replacing Scott Myers who is stepping down from the Board.
Nawal Ouzren, the CEO, said: “Khalil Barrage is a seasoned investment professional with decades of experience investing in and supporting private and public life sciences companies. We are delighted to have someone of his caliber and who knows the Company so well, steering the business as we evolve our focus into the promising area of gene therapies for the ear.”
About Khalil Barrage
Khalil Barrage has served on the Board of Sensorion for over three years, supporting several capital raises and providing leadership on the Company’s evolution towards becoming a gene therapy-focused company. He has been a managing director at Invus Group, a major investor in Sensorion, for nearly 20 years, heading its Public Equity group and serving on the Boards of Elevate Bio, Onxeo, Orthobond, and Protagenic Therapeutics. He is also a Board member of the Children of Armenia Fund and Solving Kids Cancer. Mr Barrage holds a BA from the American University of Beirut.
Khalil Barrage said: “Sensorion is a great Company with a highly compelling proposition for creating durable solutions to address inner ear disease. I’m confident that the team can help steward its promising program of gene therapy assets into clinical development. Sensorion is building an extremely high-quality leadership team, recently appointing David Lawrence as our CEO alongside Nawal. David has decades of experience in financing, capital markets, and business development. This is the right team to move Sensorion and its innovative product candidates forward and I’m excited to work with them.”
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of gene therapies to restore hearing loss disorders, a significant global unmet medical need.
Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear-related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.
It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. OTOF-GT targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on identifying biomarkers to improve the diagnosis of these underserved illnesses.
Sensorion’s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders.
Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss in January 2022.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.